# Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jeffrey R. Infante,Leslie A. Fecher,Gerald S. Falchook,Sujatha Nallapareddy,Michael S. Gordon,Carlos Becerra,Douglas J. DeMarini,Donna S. Cox,Yanmei Xu,Shannon R. Morris,Vijay Peddareddigari,Ngocdiep T. Le,Lowell L. Hart,Johanna C. Bendell,Gail Eckhardt,Razelle Kurzrock,Keith T. Flaherty,Howard A. Burris,Wells A. Messersmith |
| Citations | 559 |
| DOI | 10.1016/s1470-2045(12)70270-x |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2100738068 |
| PMID | 22805291 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Leslie A. Fecher](https://scholariq.org/researchers/leslie-a-fecher/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.